Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Gilead Sciences : offers its newest HIV drug candidate to patent pool for low-cost production

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/06/2017 | 12:13pm CEST

Gilead Sciences is licensing its newest HIV drug candidate, bictegravir, to the U.N.-backed Medicines Patent Pool, meaning it will be produced and sold at a lower cost in 116 low- and middle-income countries once it is approved.

Gilead said it will include the HIV-1 candidate in its existing agreements with generic drugmakers Sun Pharmaceutical Industries, Strides Shasun, Mylan and SeQuent Scientific, as a single agent or in fixed-dose combinations with other HIV medicines, upon regulatory approval in the U.S. It also will allow the MPP to sub-license it to other generic producers in India, China and South Africa.

Competition among manufacturers has reduced the lowest price of a Gilead HIV generic therapy by 80 percent since 2006, to as low as $3.50 per patient per month. Ninety-nine percent of people taking Gileads HIV therapies in developing countries receive generic medicine, Gilead said in an announcement today.

Of course, it is the branded version in the U.S. and Europe, where drug approvals are currently pending, that Gilead is most interested in and where it will compete with GlaxoSmithKlines $1.2 billion seller Tivicay (dolutegravir). The FDA has set a Feb.12, 2018 target date for consideration.

Analysts initially believed bictegravir, if approved, was going to be a red-hot competitor to the GSK med but phase 3 data released last spring cooled those expectations somewhat. While four studies of the investigational integrase strand transfer inhibitor hit their primary endpoints by measuring up to Tivicay and other antiretroviral agents, they didnt prove that bictegravir is superior. Then in data released today, it reported the same finding at 48 weeks.

GSK, which has been aggressively building its HIV focused ViiV Healthcare, is taking another tack in its assault on market leader Gileads $10 billion-plus HIV franchise. The U.K.-based company is betting on a two-drug, dolutegravir-containing regimen that could potentially cut down on the side-effect burden of Gileads three-drug approaches, and their cost, too.

(c) International 2006-2017, SANA Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
10/16 GILEAD SCIENCES : Awards $7.5 Million in Second Round of Grants to Advance HIV C..
10/16 GILEAD SCIENCES : to Release Third Quarter 2017 Financial Results on Thursday Oc..
10/12 GILEAD SCIENCES : An Application for the Trademark "NASH360" Has Been Filed by G..
10/12 GILEAD SCIENCES : High-Stakes Gilead Case Lands Fish & Richardson Principals Jua..
10/12 GILEAD SCIENCES : Completes Acquisition of Kite Pharma, Inc.
10/12 GILEAD SCIENCES : to Release Third Quarter 2017 Financial Results on Thursday, O..
10/12 GILEAD SCIENCES : Presents Results From Phase 3 Study Evaluating Patients Who Sw..
10/12 GILEAD SCIENCES : Patent Issued for Co-Crystals, Salts and Solid Forms of Tenofo..
10/12 GILEAD SCIENCES : Announces New License Agreement With the Medicines Patent Pool..
10/12 Loncar Cancer Immunotherapy Index Announces Merger Replacements
More news
News from SeekingAlpha
10/16 President Trump at it again with comments on "out of control" drug prices
10/16 GILEAD : My Only 'Buy 'Til You Die' Investment,  A Deep Due Diligence Dive
10/16 Q3 ROUNDUP : Top 5 Performing Knives
10/15 DIVIDEND INCOME UPDATE : September 2017
10/12 MONTHLY REVIEW OF DIVGRO : September 2017
Financials ($)
Sales 2017 25 905 M
EBIT 2017 16 060 M
Net income 2017 10 607 M
Debt 2017 12 394 M
Yield 2017 2,61%
P/E ratio 2017 10,13
P/E ratio 2018 11,92
EV / Sales 2017 4,57x
EV / Sales 2018 5,04x
Capitalization 106 B
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 84,4 $
Spread / Average Target 3,9%
EPS Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES13.35%106 002
REGENERON PHARMACEUTICALS20.67%47 464
VERTEX PHARMACEUTICALS107.56%38 551
ACTELION23.24%29 919
GENMAB22.08%13 910
EXELIXIS, INC.66.06%7 277